{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:54:52Z","timestamp":1789779292158,"version":"4.0.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,29]]},"DOI":"10.7759\/cureus.98114","type":"journal-article","created":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T03:44:30Z","timestamp":1764474270000},"source":"Crossref","is-referenced-by-count":1,"title":["Nandrolone Decanoate for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Trials"],"prefix":"10.7759","author":[{"given":"Lucas C","family":"Camara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus H","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson C","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center JR","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999, 353:878-82. 10.1016\/S0140-6736(98)09075-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0852","article-title":"Effect of osteoporosis treatment on mortality: a meta-analysis","volume":"95","author":"Bolland MJ","year":"2010","unstructured":"Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010, 95:1174-81. 10.1210\/jc.2009-0852","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20251847","article-title":"The rising global burden of osteoporosis: insights into prevalence, fracture rates, and future trends","volume":"14","author":"Vijayakumar S","year":"2025","unstructured":"Vijayakumar S, Parimalakrishnan S, Prem Anand DC, Monisha S, Vishnuvarthini, Vijayakumar AR. The rising global burden of osteoporosis: insights into prevalence, fracture rates, and future trends. Int J Basic Clin Pharmacol. 2025, 14:603-13. 10.18203\/2319-2003.ijbcp20251847","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari N","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, Mohammadi M. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021, 16:609. 10.1186\/s13018-021-02772-0","journal-title":"J Orthop Surg Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate-associated adverse events","volume":"8","author":"Papapetrou PD","year":"2009","unstructured":"Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009, 8:96-110. 10.14310\/horm.2002.1226","journal-title":"Hormones (Athens)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update","volume":"105","author":"Shoback D","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020, 105:587-94. 10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag KG","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, et al.. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017, 377:1417-27. 10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9554-2","article-title":"The use of combination therapy in the treatment of postmenopausal osteoporosis","volume":"41","author":"Compston J","year":"2012","unstructured":"Compston J. The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine. 2012, 41:11-8. 10.1007\/s12020-011-9554-2","journal-title":"Endocrine"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010129","article-title":"Association of sarcopenia with osteopenia and osteoporosis in community-dwelling older Korean adults: a cross-sectional study","volume":"11","author":"Lee DY","year":"2021","unstructured":"Lee DY, Shin S. Association of sarcopenia with osteopenia and osteoporosis in community-dwelling older Korean adults: a cross-sectional study. J Clin Med. 2021, 11:129. 10.3390\/jcm11010129","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146924","article-title":"Rethinking osteoporosis drugs: can we simultaneously address sarcopenia?","volume":"26","author":"Gavrilov Z","year":"2025","unstructured":"Gavrilov Z, Lojk J. Rethinking osteoporosis drugs: can we simultaneously address sarcopenia?. Int J Mol Sci. 2025, 26:6924. 10.3390\/ijms26146924","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/isj.isj_2_23","article-title":"An academic clinical study to assess the efficacy and safety of nandrolone decanoate and alendronate compared with alendronate alone in patients with osteoporosis","volume":"6","author":"Dave BR","year":"2023","unstructured":"Dave BR, Bali SA, Degulmadi D, Krishnan AM, Mayi S, Ranjan R. An academic clinical study to assess the efficacy and safety of nandrolone decanoate and alendronate compared with alendronate alone in patients with osteoporosis. Indian Spine J. 2023, 6:146-51. 10.4103\/isj.isj_2_23","journal-title":"Indian Spine J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(95)00056-6","article-title":"Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens","volume":"53","author":"Sundaram K","year":"1995","unstructured":"Sundaram K, Kumar N, Monder C, Bardin CY. Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens. J Steroid Biochem Mol Biol. 1995, 53:253-7. 10.1016\/0960-0760(95)00056-6","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84726","article-title":"Investigating the role of nandrolone decanoate in the management of osteosarcopenia in postmenopausal women: a prospective observational study","volume":"17","author":"Dave B","year":"2025","unstructured":"Dave B, Agarawal S, Krishnan A, Mayi S, Rai RR, Dave MB, Anil A. Investigating the role of nandrolone decanoate in the management of osteosarcopenia in postmenopausal women: a prospective observational study. Cureus. 2025, 17:e84726. 10.7759\/cureus.84726","journal-title":"Cureus"},{"key":"ref14","unstructured":"Product information. (2024). Accessed. November 15, 2025: https:\/\/health-products.canada.ca\/dpd-bdpp\/info?code=1640&lang=eng."},{"key":"ref15","unstructured":"Deca-Durabolin 50 mg\/mL. (2025). Accessed. November 15, 2025: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/37122d6def7564b4c07675e140509b9c1f43f76a."},{"key":"ref16","unstructured":"Deca-Durabolin\u00ae. (2022). Accessed. November 15, 2025: https:\/\/consultas.anvisa.gov.br\/#\/bulario\/detalhe\/1189598?nomeProduto=Deca-Durabolin."},{"key":"ref17","unstructured":"Label. nandrolone decanoate-nandrolone decanoate injection. (2025). Accessed: November 15, 2025: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a586b484-1b46-40b9-9508-fd28002ad383."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11888","article-title":"Research advances in crosstalk between muscle and bone in osteosarcopenia (review)","volume":"25","author":"Yu C","year":"2023","unstructured":"Yu C, Du Y, Peng Z, et al.. Research advances in crosstalk between muscle and bone in osteosarcopenia (review). Exp Ther Med. 2023, 25:189. 10.3892\/etm.2023.11888","journal-title":"Exp Ther Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(93)90049-N","article-title":"Effects of nandrolone decanoate on bone mass in established osteoporosis","volume":"17","author":"Passeri M","year":"1993","unstructured":"Passeri M, Pedrazzoni M, Pioli G, et al.. Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas. 1993, 17:211-9. 10.1016\/0378-5122(93)90049-N","journal-title":"Maturitas"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/60.5.648","article-title":"The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial","volume":"60","author":"Frisoli A Jr","year":"2005","unstructured":"Frisoli A Jr, Chaves PH, Pinheiro MM, Szejnfeld VL. The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2005, 60:648-53. 10.1093\/gerona\/60.5.648","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem A","year":"2023","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al.. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023, 176:224-38. 10.7326\/M22-1034","journal-title":"Ann Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-024-01441-z","article-title":"Similarities and differences between European guidelines for the management of postmenopausal osteoporosis","volume":"19","author":"Cortet B","year":"2024","unstructured":"Cortet B, Gua\u00f1abens N, Brandi ML, Siggelkow H. Similarities and differences between European guidelines for the management of postmenopausal osteoporosis. Arch Osteoporos. 2024, 19:84. 10.1007\/s11657-024-01441-z","journal-title":"Arch Osteoporos"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref24","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (Updated August 2024)","year":"2019","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (Updated August 2024). Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (ed). John Wiley & Sons, Chichester, UK; 2019."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref28","unstructured":"The R Project for Statistical Computing. (2025). Accessed. November 15, 2025: https:\/\/www.r-project.org\/."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi S","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019, 22:153-60. 10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham H","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, et al.. Welcome to the Tidyverse. J Open Source Softw. 2019, 4:1686. 10.21105\/joss.01686","journal-title":"J Open Source Softw"},{"key":"ref31","article-title":"Ggplot2: Elegant Graphics for Data Analysis","author":"Wickham H","year":"2016","unstructured":"Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer, Cham, Switzerland; 2016."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt G","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al.. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011, 64:383-94. 10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(89)90210-7","article-title":"Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study","volume":"11","author":"Gennari C","year":"1989","unstructured":"Gennari C, AgnusDei D, Gonnelli S, Nardi P. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study. Maturitas. 1989, 11:187-97. 10.1016\/0378-5122(89)90210-7","journal-title":"Maturitas"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(89)90081-4","article-title":"Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women","volume":"38","author":"Hassager C","year":"1989","unstructured":"Hassager C, P\u00f8denphant J, Riis BJ, Johansen JS, Jytte J, Christiansen C. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism. 1989, 38:238-42. 10.1016\/0026-0495(89)90081-4","journal-title":"Metabolism"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/0169-6009(89)90025-1","article-title":"Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?","volume":"6","author":"Johansen JS","year":"1989","unstructured":"Johansen JS, Hassager C, Podenphant J, et al.. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?. Bone Miner. 1989, 6:77-86. 10.1016\/0169-6009(89)90025-1","journal-title":"Bone Miner"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1220715","article-title":"Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitonin","volume":"122","author":"Hartwell D","year":"1990","unstructured":"Hartwell D, Hassager C, Overgaard K, Riis BJ, P\u00f8denphant JR, Christiansen C. Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitonin. Acta Endocrinol (Copenh). 1990, 122:715-21. 10.1530\/acta.0.1220715","journal-title":"Acta Endocrinol (Copenh)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/BF01621912","article-title":"Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate","volume":"3 Suppl 1","author":"Need AG","year":"1993","unstructured":"Need AG, Nordin BE, Chatterton BE. Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate. Osteoporos Int. 1993, 3 Suppl 1:218-22. 10.1007\/BF01621912","journal-title":"Osteoporos Int"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell O","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A, et al.. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005, 20:1185-94. 10.1359\/JBMR.050304","journal-title":"J Bone Miner Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall D","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996, 312:1254-9. 10.1136\/bmj.312.7041.1254","journal-title":"BMJ"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black DM","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al.. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003, 349:1207-15. 10.1056\/NEJMoa031975","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer RM","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al.. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001, 344:1434-41. 10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2003.09.004","article-title":"Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale","volume":"8","author":"Salaffi F","year":"2004","unstructured":"Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004, 8:283-91. 10.1016\/j.ejpain.2003.09.004","journal-title":"Eur J Pain"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar JT","year":"2001","unstructured":"Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001, 94:149-58. 10.1016\/S0304-3959(01)00349-9","journal-title":"Pain"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20543","article-title":"Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)","volume":"63 Suppl 11","author":"Hawker GA","year":"2011","unstructured":"Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011, 63 Suppl 11:S240-52. 10.1002\/acr.20543","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-025-01230-y","article-title":"The association between muscle mass and change in physical functioning in older adults: a systematic review and meta-analysis of prospective studies","volume":"16","author":"Visser M","year":"2025","unstructured":"Visser M, S\u00e4\u00e4ksj\u00e4rvi K, Burchell GL, Schaap LA. The association between muscle mass and change in physical functioning in older adults: a systematic review and meta-analysis of prospective studies. Eur Geriatr Med. 2025, 16:1731-48. 10.1007\/s41999-025-01230-y","journal-title":"Eur Geriatr Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.109s0045","article-title":"Anabolic steroids and osteoporosis","volume":"271","author":"Dequeker J","year":"1985","unstructured":"Dequeker J, Geusens P. Anabolic steroids and osteoporosis. Acta Endocrinol Suppl (Copenh). 1985, 271:45-52. 10.1530\/acta.0.109s0045","journal-title":"Acta Endocrinol Suppl (Copenh)"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.9734\/jammr\/2023\/v35i205179","article-title":"Lean body mass in osteoporotic postmenopausal women treated with nandrolone decanoate: a systematic search review","volume":"35","author":"C\u00e2mara LC","year":"2023","unstructured":"C\u00e2mara LC, Starling MA, Canvilo LM, Civile V, Civile VF. Lean body mass in osteoporotic postmenopausal women treated with nandrolone decanoate: a systematic search review. J Adv Med Med Res. 2023, 35:105-13. 10.9734\/jammr\/2023\/v35i205179","journal-title":"J Adv Med Med Res"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.1016\/S0025-6196(19)30667-6","article-title":"Potential anabolic effects of androgens on bone","volume":"79","author":"Kearns AE","year":"2004","unstructured":"Kearns AE, Khosla S. Potential anabolic effects of androgens on bone. Mayo Clin Proc. 2004, 79:S14-8.","journal-title":"Mayo Clin Proc"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/0169-6009(92)90811-q","article-title":"Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis?","volume":"18","author":"Birkenh\u00e4ger JC","year":"1992","unstructured":"Birkenh\u00e4ger JC, Erdtsieck RJ, Zeelenberg J, et al.. Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis?. Bone Miner. 1992, 18:251-65. 10.1016\/0169-6009(92)90811-q","journal-title":"Bone Miner"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-6009(08)80194-8","article-title":"Effect of nandrolone decanoate and 1-alpha-hydroxy-calciferol on patients with vertebral osteoporotic collapse. A double-blind clinical trial","volume":"27","author":"Lyritis GP","year":"1994","unstructured":"Lyritis GP, Androulakis C, Magiasis B, Charalambaki Z, Tsakalakos N. Effect of nandrolone decanoate and 1-alpha-hydroxy-calciferol on patients with vertebral osteoporotic collapse. A double-blind clinical trial. Bone Miner. 1994, 27:209-17. 10.1016\/s0169-6009(08)80194-8","journal-title":"Bone Miner"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/BF00297289","article-title":"Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine","volume":"50","author":"Sz\u00fccs J","year":"1992","unstructured":"Sz\u00fccs J, Horv\u00e1th C, Kollin E, Szathm\u00e1ri M, Holl\u00f3 I. Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. Calcif Tissue Int. 1992, 50:7-10. 10.1007\/BF00297289","journal-title":"Calcif Tissue Int"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/s8756-3282(96)90164-7","article-title":"Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women","volume":"19","author":"Eiken P","year":"1996","unstructured":"Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone. 1996, 19:191S-3S. 10.1016\/s8756-3282(96)90164-7","journal-title":"Bone"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.5114\/pm.2014.44996","article-title":"Hormone replacement therapy and the prevention of postmenopausal osteoporosis","volume":"13","author":"Gambacciani M","year":"2014","unstructured":"Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Prz Menopauzalny. 2014, 13:213-20. 10.5114\/pm.2014.44996","journal-title":"Prz Menopauzalny"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.7.815","article-title":"Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial","volume":"286","author":"Villareal DT","year":"2001","unstructured":"Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA. 2001, 286:815-20. 10.1001\/jama.286.7.815","journal-title":"JAMA"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/BF02210686","article-title":"Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis","volume":"14 Suppl 3","author":"Geusens P","year":"1995","unstructured":"Geusens P. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol. 1995, 14 Suppl 3:32-9. 10.1007\/BF02210686","journal-title":"Clin Rheumatol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher D","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, et al.. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340:c869. 10.1136\/bmj.c869","journal-title":"BMJ"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.273.5.408","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz KF","year":"1995","unstructured":"Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995, 273:408-12. 10.1001\/jama.273.5.408","journal-title":"JAMA"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107 J","year":"2012","unstructured":"Savovi\u0107 J, Jones H, Altman D, et al.. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess. 2012, 16:1-82. 10.3310\/hta16350","journal-title":"Health Technol Assess"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1119","article-title":"Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors","volume":"344","author":"Hr\u00f3bjartsson A","year":"2012","unstructured":"Hr\u00f3bjartsson A, Thomsen AS, Emanuelsson F, et al.. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012, 344:e1119. 10.1136\/bmj.e1119","journal-title":"BMJ"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2017.24.1.37","article-title":"The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis","volume":"24","author":"Byun JH","year":"2017","unstructured":"Byun JH, Jang S, Lee S, Park S, Yoon HK, Yoon BH, Ha YC. The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis. J Bone Metab. 2017, 24:37-49. 10.11005\/jbm.2017.24.1.37","journal-title":"J Bone Metab"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel MN","year":"2023","unstructured":"H\u00e4ndel MN, Cardoso I, von B\u00fclow C, et al.. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 2023, 381:e068033. 10.1136\/bmj-2021-068033","journal-title":"BMJ"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.6745","article-title":"Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials","volume":"182","author":"Deardorff WJ","year":"2022","unstructured":"Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials. JAMA Intern Med. 2022, 182:33-41. 10.1001\/jamainternmed.2021.6745","journal-title":"JAMA Intern Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-024-01447-7","article-title":"Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Li M","year":"2024","unstructured":"Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024, 19:89. 10.1007\/s11657-024-01447-7","journal-title":"Arch Osteoporos"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-023-03920-4","article-title":"Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis","volume":"18","author":"Yuan C","year":"2023","unstructured":"Yuan C, Liang Y, Zhu K, Xie W. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. J Orthop Surg Res. 2023, 18:447. 10.1186\/s13018-023-03920-4","journal-title":"J Orthop Surg Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai JN","year":"2016","unstructured":"Tsai JN, Uihlein AV, Burnett-Bowie SM, et al.. Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab. 2016, 101:2023-30. 10.1210\/jc.2016-1160","journal-title":"J Clin Endocrinol Metab"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431676","article-title":"Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis","volume":"15","author":"Yang J","year":"2024","unstructured":"Yang J, Guo X, Cui Z, Guo H, Dong JN. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024, 15:1431676. 10.3389\/fendo.2024.1431676","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100729","article-title":"Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: systemic review and meta-analysis","volume":"13","author":"Wu CH","year":"2020","unstructured":"Wu CH, Hung WC, Chang IL, et al.. Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: systemic review and meta-analysis. Bone Rep. 2020, 13:100729. 10.1016\/j.bonr.2020.100729","journal-title":"Bone Rep"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black DM","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, et al.. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020, 383:743-53. 10.1056\/NEJMoa1916525","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.3.373","article-title":"An exercise in geometry","volume":"17","author":"Seeman E","year":"2002","unstructured":"Seeman E. An exercise in geometry. J Bone Miner Res. 2002, 17:373-80. 10.1359\/jbmr.2002.17.3.373","journal-title":"J Bone Miner Res"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black DM","year":"2016","unstructured":"Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016, 374:254-62. 10.1056\/NEJMcp1513724","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/429199-nandrolone-decanoate-for-postmenopausal-osteoporosis-a-systematic-review-and-meta-analysis-of-randomized-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T03:44:31Z","timestamp":1764474271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/429199-nandrolone-decanoate-for-postmenopausal-osteoporosis-a-systematic-review-and-meta-analysis-of-randomized-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":70,"URL":"https:\/\/doi.org\/10.7759\/cureus.98114","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}